Clinical trial NCT01453803: Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease
Official title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously and Intranasally in Patients With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Parkinson's Disease
Keywords: Liposuction
ADSC
ASC
stem cell
Parkinson's Disease
Parkinson's
therapy
Lead sponsor: Ageless Regenerative Institute
Sponsor class: INDUSTRY
First posted: 2011-10-18
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The intent of this clinical study is to answer the questions:

1. Is the proposed treatment safe
2. Is treatment effective in improving the disease pathology of patients with Parkinson's Disease and clinical outcomes.

Detailed description: This will be an open-label, non-randomized multi-center patient sponsored study of Adipose-Derived Stromal Cells (ASC) implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the Vertebral Artery and intravenously.

Eligibility criteria: Inclusion Criteria:

* Males and Females between Age 18 and 80 years.
* Patient with current diagnosis of PD with motor complications (as confirmed by neurologist) as per the standard criteria and guidelines.
* Responsiveness to Levodopa or dopa agonist. This is defined as improvement between Off and On UPDRS by at least 33% of the Motor UPDRS.
* PD of Stage 2.5, 3 \& 4 of HOEHN \& YAHR staging.
* Stable Parkinsonian medications for the 60 days prior to the surgical therapy.
* MRI not showing gross atrophy or any other pathology of brain.
* Patients with score less than 19 for the Montgomery-Asberg Rating Scale (MADRS) for Depression.
* NO Significant cognitive impairment.MMSE \> 21.
* Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

* History of intracranial surgeries or implantation of a device for Parkinson's disease two years prior to treatment.
* History of psychiatric disorders like schizophrenia or psychotic disorders.
* History of other malignancy, with the exception of treated cutaneous squamous cell or basal cell carcinoma, within 5 years.
* Contraindication for MRI
* Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
* Life expectancy \< 6 months due to concomitant illnesses.
* Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
* Active infectious disease. Patients known to have tested positive for HIV, HTLV, HBV, HCV, CMV (IgM \> IgG) and/or syphilis will be evaluated by an expert as to patient eligibility based on the patient's infectious status
* Any illness which, in the Investigator's judgement, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
* Patients on chronic immunosuppressive transplant therapy
* Systolic blood pressure (supine) ≤90 mmHg;
* Resting heart rate \> 100 bpm;
* Active clinical infection being treated by antibiotics within one week of enrollment.
* Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
* History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last two years.
* Unwilling and/or not able to give written informed consent.

Primary outcomes:
measure: UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE)-Behavior
timeFrame: 3 months
measure: Number of participants with adverse events
timeFrame: 1 week
measure: UPDRS- Improvement in Activities of Daily Living
timeFrame: 3 months
measure: UPDRS- Improvement in motor Examination
timeFrame: 3 months
measure: UPDRS- MODIFIED HOEHN AND YAHR STAGING
timeFrame: 3 months
measure: UPDRS- SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE
timeFrame: 3 months
measure: UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE)Behavior
timeFrame: 6 months
measure: Number of participants with adverse events
timeFrame: 2 weeks
measure: Number of participants with adverse events
timeFrame: 4 weeks
measure: UPDRS- Improvement in Activities of Daily Living
timeFrame: 6 months
measure: UPDRS- Improvement in motor Examination
timeFrame: 6 months
measure: UPDRS- MODIFIED HOEHN AND YAHR STAGING
timeFrame: 6 months
measure: UPDRS- SCHWAB AND ENGLAND ACTIVITIES OF DAILY LIVING SCALE
timeFrame: 6 months
Secondary outcomes:
measure: Reduction of Parkinson's medications
timeFrame: 3 months
measure: Improvement in subjective symptoms: facial expression, gait, and freezing
timeFrame: 3 months
measure: Reduction of Parkinson's medications
timeFrame: 6 months
measure: Improvement in subjective symptoms: facial expression, gait, and freezing
timeFrame: 6 months
Other outcomes:
Locations:
city: Aventura
country: United States
facility: Ageless Regenerative Institute LLC
state: Florida
Study officials:
affiliation: Ageless Regenerative Institute
name: Sharon McQuillan, MD
role: PRINCIPAL_INVESTIGATOR
References: